Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
AssigneesBayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
InventorAntje Margret Wengner
Life of this patent
Estimating the term…
Abstract
The present invention covers combinations of at least two components, component A and component B, comprising component A being an inhibitor of ATR kinase, particularly an inhibitor of ATR kinase selected from VX-803, VX-970, AZD-6738, a compound of general formula (I) described herein, a compound of general formula (Ib) described herein and Compound A described infra, and component B being a PD-1/PD-L1 inhibitor described herein. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.
Claims15
A method for treatment of a hyper-proliferative disease that is a cancer, comprising administering to a patient in need thereof, an effective amount of a combination-comprising at least two components, component A and component B, wherein component A is an inhibitor of ATR kinase having the structure:
- or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof;
- and wherein component B is a PD-1 inhibitor or a PD-L1 inhibitor, and wherein component B is administered to the patient prior to the first administration of component A.
Dependencies are inferred from the claim text.